ASMB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States...

Stats
Today's Volume	6 103.00
Average Volume	26 870.00
Market Cap	73.25M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-2.74 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.000
ATR14	$0.109 (0.81%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Mchutchison John G	Sell	1 206	Common Stock
2024-03-29	Bjorkquist Jeanette M	Buy	850	Common Stock
2024-04-01	Bjorkquist Jeanette M	Sell	114	Common Stock
2024-03-29	Bjorkquist Jeanette M	Buy	1 550	Stock Option (right to buy)
2024-03-29	White Nicole S	Buy	17 500	Stock Option (right to buy)

INSIDER POWER
65.40
Last 96 transactions
Buy: 4 380 980 \| Sell: 646 377

Assembly Biosciences Inc Correlation

10 Most Positive Correlations
CYAN	0.933
EYEG	0.925
AGFY	0.923
FTFT	0.908
CPIX	0.908
SRTS	0.906
AFIB	0.905
ACER	0.904
DSWL	0.9
ATHA	0.9

10 Most Negative Correlations
DNUT	-0.904
NRDS	-0.897
DSPG	-0.897
EPZM	-0.893
XOG	-0.892
SGEN	-0.889
CNCE	-0.885
TYHT	-0.881
BTBD	-0.875
STAY	-0.874

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Assembly Biosciences Inc Financials

Annual	2023
Revenue:	$7.16M
Gross Profit:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2023
Revenue:	$7.16M
Gross Profit:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2022
Revenue:	$0
Gross Profit:	$-498 000 (0.00 %)
EPS:	$-22.82

FY	2021
Revenue:	$6.25M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.67

Financial Reports:

No articles found.

Assembly Biosciences Inc

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.